NYSE:BAXBaxter International Stock Price, Forecast & News

Baxter International's stock was trading at $77.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BAX stock has increased by 16.7% and is now trading at $90.98. View which stocks have been most impacted by Coronavirus.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International.

Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Baxter International.

Baxter International Inc (NYSE:BAX) announced its earnings results on Thursday, April, 30th. The medical instruments supplier reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.09. The medical instruments supplier earned $2.80 billion during the quarter, compared to the consensus estimate of $2.74 billion. Baxter International had a return on equity of 22.70% and a net margin of 8.85%. Baxter International's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.76 EPS. View Baxter International's earnings history.

Baxter International declared a quarterly dividend on Tuesday, May 5th. Shareholders of record on Friday, June 5th will be paid a dividend of $0.245 per share on Wednesday, July 1st. This represents a $0.98 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date of this dividend is Thursday, June 4th. This is an increase from Baxter International's previous quarterly dividend of $0.22. View Baxter International's dividend history.

Baxter International announced that its board has authorized a stock repurchase plan on Tuesday, November 13th 2018, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 6.1% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its stock is undervalued.

Baxter International updated its first quarter earnings guidance on Tuesday, March, 17th. The company provided EPS guidance of $0.72-0.74 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.81.

19 Wall Street analysts have issued 1-year price targets for Baxter International's stock. Their forecasts range from $84.00 to $105.00. On average, they expect Baxter International's share price to reach $96.42 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View analysts' price targets for Baxter International.

News headlines about BAX stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Baxter International earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutBaxter International.

Baxter International saw a decline in short interest in May. As of May 15th, there was short interest totaling 5,570,000 shares, a decline of 14.6% from the April 30th total of 6,520,000 shares. Based on an average daily volume of 3,330,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.1% of the company's shares are sold short. View Baxter International's Current Options Chain.

Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Masimo (MASI) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Honeywell International (HON), Cisco Systems (CSCO), AT&T (T), Pfizer (PFE), BlackRock (BLK), Verizon Communications (VZ), Abbott Laboratories (ABT) and Procter & Gamble (PG).

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Baxter International's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.14%), Wellington Management Group LLP (5.90%), State Street Corp (4.63%), Morgan Stanley (3.83%), Third Point LLC (2.28%) and Veritas Asset Management LLP (1.76%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International.

BAX stock was sold by a variety of institutional investors in the last quarter, including Third Point LLC, Wellington Management Group LLP, Eaton Vance Management, First Trust Advisors LP, Mackenzie Financial Corp, Prudential PLC, AQR Capital Management LLC, and Skandinaviska Enskilda Banken AB publ . Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, and John D Forsyth. View insider buying and selling activity for Baxter International.

BAX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Capital International Investors, Veritas Asset Management LLP, Morgan Stanley, Bessemer Group Inc., Nuveen Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, and Sumitomo Mitsui Trust Holdings Inc.. View insider buying and selling activity for Baxter International.

Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BAX stock can currently be purchased for approximately $90.98.

Baxter International has a market capitalization of $46.15 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe.

The official website for Baxter International is www.baxter.com.

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]